Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
This study evaluated the anxiolytic efficacy, safety and tolerability of a flexible dose of venlafaxine extended release (ER) compared with placebo and paroxetine in the short‐term treatment of generalized social anxiety disorder (SAD). Adult outpatients with generalized SAD (n = 434) were randomized to receive capsules of venlafaxine ER 75 mg to 225 mg/day, paroxetine 20 mg to 50 mg/day, or placebo for 12 weeks. The primary efficacy variable was the Liebowitz social anxiety scale total score. Secondary efficacy variables included the patient‐rated social phobia inventory and the proportion of responders in each group (a responder was defined as having a clinical global impression‐improvement score of 1 or 2). Treatment with venlafaxine ER was associated with significantly greater improvement than treatment with placebo for all primary and secondary efficacy variables (p < 0.05). No significant differences in primary or secondary efficacy variables were observed between the venlafaxine ER and paroxetine groups. The week 12 response rates were 69%, 66% and 36% for the venlafaxine ER, paroxetine and placebo groups, respectively. Both active treatments were generally well tolerated and were associated with a similar incidence of adverse events. This study shows that venlafaxine ER is an effective, safe and well‐tolerated drug treatment for SAD. Copyright © 2004 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Psychometric properties of the Social Phobia Inventory (SPIN): New self-rating scale
Connor, K. M., Davidson, J. R. T., Churchill, L. E., Sherwood, A., Weisler, R. H., & Foa, E. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.379 · Cited by 1,624
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987 · cited 5×
“In addition, treatment with venlafaxine ER was associated with significant improvement in psychosocial functioning, as demonstrated by results on the SDI and WPAI.”
MethodInfluentialSocial Phobia Symptoms, Subtypes, and Severity: Findings From a Community Survey
Stein, M. B., Torgrud, L. J., & Walker, J. R. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.11.1046 · Cited by 266
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175 · cited 2×
“…inhibitor (SNRI) venlafaxine extended release (ER) in relieving symptoms of depression and generalized anxiety disorder (Silverstone and Ravindran, 1999; Feighner et al., 1998; Khan et al., 1998; Allgulander et al., 2001; Gelenberg et al., 2000; Rickels et al., 2000; Davidson et al., 1999).”
BackgroundSelf-citationPharmacotherapy of social anxiety disorder
Blanco, C., Antia, S. X., & Liebowitz, M. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01294-x · Cited by 88
Walker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84 · cited 4×
“, 2002) and sertraline (Walker et al., 2000) reported efficacy in preventing relapse in patients who had successfully completed short-term treatment, and there is evidence that venlafaxine ER is effective for long-term (>24-week) treatment of generalized SAD (Stein and Mangano, 2002).”
BackgroundInfluentialComorbidities in social phobia
Lecrubier, Y., & Weiller, E. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199710006-00004 · Cited by 73
Research works printed but not linked: 43
- 10.1111/j.1600-0447.1999.tb10845.x · DOI · Paper page
- 10.1097/00004850-199907000-00006 · DOI · Paper page
- American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders
- American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders
- 10.1192/bjp.175.2.120 · DOI · Paper page
- Ballenger JC, 1999, Clinical guidelines for establishing remission in patients with depression and anxiety, J Clin Psychiatry, 60, 29
- Ballenger JC, 2001, Treatment of anxiety disorders to remission, J Clin Psychiatry, 62, 5
- Ballenger JC, 1998, Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety, J Clin Psychiatry, 59, 60
- 10.4088/JCP.v60n0805 · DOI · Paper page
- 10.1001/archpsyc.1994.03950120047008 · DOI · Paper page
- 10.1016/S0165-0327(97)00109-2 · DOI
- FurmarkT.2000.Social Phobia. From Epidemiology to Brain Function. Dissertation the Faculty of Social Sciences Uppsala University Sweden.
- 10.1001/jama.283.23.3082 · DOI · Paper page
- Guy W, 1976, ECDEU Assessment Manual for Psychopharmacology
- 10.1016/S0924-977X(03)92184-5 · doi:10.1016/s0924-977x(03)92184-5
- 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- 10.1016/S0006-3223(01)01183-0 · DOI · Paper page
- 10.1016/S0165-1781(03)00071-4 · DOI
- Judd LL, 1994, Social phobia: a clinical overview, J Clin Psychiatry, 55, 5
- 10.1176/appi.ajp.158.12.1999 · DOI · Paper page
- Kelsey JE, 1995, Venlafaxine in social phobia, Psychopharmacol Bull, 31, 767
- 10.1097/00004714-199802000-00004 · DOI · Paper page
- 10.1002/(SICI)1520-6394(1999)10:3<89::AID-DA1>3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
- Liebowitz MR, 2002, Venlafaxine XR in generalized social anxiety disorder, Int J Neuropsychopharmacol, 5, S211
- Liebowitz MR, 2002, Efficacy of venlafaxine XR in generalized social anxiety disorder, Int J Neuropsychopharmacol, 5, S211
- Lipman RS, 1982, Differentiating anxiety and depression in anxiety disorders: use of rating scales, Psychopharmacol Bull, 18, 69
- 10.1046/j.1365-2796.2001.00881.x · DOI
- 10.1016/S0006-3223(01)01309-9 · DOI · Paper page
- Morrow JD, 2003, Pentagastrin‐induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol, J Psychiatry Neurosci, 28, 127
- 10.1097/00005053-196901000-00010 · DOI · Paper page
- 10.1176/ajp.145.5.590 · DOI · Paper page
- 10.2165/00019053-199304050-00006 · DOI · Paper page
- 10.1176/appi.ajp.157.6.968 · DOI · Paper page
- Sheehan DV, 1998, The Mini‐International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10, J Clin Psychiatry, 59, 22
- 10.1111/j.1600-0447.1996.tb10624.x · doi:10.1111/j.1600-0447.1996.tb10624.x
- 10.4088/JCP.v60n0105 · DOI · Paper page
- 10.1176/appi.ps.53.6.714 · DOI · Paper page
- 10.1001/archpsyc.59.12.1111 · DOI · Paper page
- 10.1097/00004714-199606000-00005 · DOI · Paper page
- 10.1176/ajp.156.5.756 · DOI · Paper page
- 10.1001/jama.280.8.708 · DOI · Paper page
- 10.1192/bjp.178.3.234 · DOI · Paper page
- 10.1176/appi.ajp.158.2.275 · DOI · Paper page
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Paroxetine [431,438-444] 1 Phenelzine [384,386,418,461,462] 1”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…but alprazolam was not [I (PCT)] (Gelernter et al., 1991); and escitalopram was found superior to paroxetine [I (PCT)] (Lader et al., 2004); venlafaxine and paroxetine had similar overall efficacy in two placebo-controlled studies [I (PCT)] (Allgulander et al., 2004b; Liebowitz et al., 2005).”
BackgroundResultSelf-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Metadata
- Authors
- Allgulander, C., Mangano, R., Zhang, J., Dahl, A. A., Lepola, U., Sjödin, I., & Emilien, G.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2004-06-15
- Volume
- 19
- Issue
- 6
- Pages
- 387-396
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1964802747
- Cited by
- 111
- References
- 9
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine. https://app.cochat.ai/papers/10.1002/hup.602
- The paper
- Allgulander, C., Mangano, R., Zhang, J., Dahl, A. A., Lepola, U., Sjödin, I., & Emilien, G. (2004). Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.602
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.